PRINCETON, N.J., Sept. 19, 2023 /PRNewswire/ -- WCG, the global leader in providing solutions that measurably improve and accelerate clinical research, will share how to safely use artificial intelligence to advance clinical trials, as presented by Paul Mancinellli, PhD, WCG's Chief Technology Officer, at the 13th annual DPHARM conference taking place in Boston, MA, September 20 – 22, 2023..

普林斯顿，新泽西州，2023年9月19日/PRNewswire/-WCG是提供可测量改进和加速临床研究解决方案的全球领导者，将分享如何安全地使用人工智能推进临床试验，正如Paul Mancinelli博士WCG首席技术官在第13届年度DPHARM会议上于2023年9月20日至22日在马萨诸塞州波士顿举行。。

Dr. Mancinelli's presentation, titled 'Deploying AI Across the Clinical Trial Life Cycle to Deliver Efficient, Safe and Impactful Clinical Research,' will cover case examples that highlight the impact of machine learning and large language models while exploring an interoperable platform that drives efficiency and safety in clinical trial operations.

Mancinelli博士的演讲题为“在临床试验生命周期中部署AI以提供高效，安全和有影响力的临床研究”，将涵盖案例，突出机器学习和大型语言模型的影响，同时探索可互操作的平台，提高效率和临床试验操作的安全性。

He will educate on the use of machine learning to mitigate trial risks, reduce costs, and detect anomalies systematically, and how AI tools may be able to assist with legal and regulatory compliance..

他将教育如何使用机器学习来减轻试验风险，降低成本并系统地检测异常情况，以及AI工具如何能够协助法律和法规遵从。。

'The plug and play nature of today's AI ecosystem provides immediate opportunities to improve safety and efficacy in clinical trials,' remarked Dr. Mancinelli. 'I am thrilled to share my expertise with the DPHARM community, separating AI fact from fiction and digging into how all of us can make a measurable impact across the industry with the use of AI.'.

Mancinelli博士说：“当今人工智能生态系统的即插即用特性为提高临床试验的安全性和有效性提供了即时机会。”我很高兴与DPHARM社区分享我的专业知识，将人工智能事实与虚构分开，并挖掘我们所有人如何通过使用人工智能在整个行业产生可衡量的影响。

'Our mission of accelerating clinical research, together, transcends our WCG clients,' added Chief Executive Officer Sam Srivastava. 'When we can share our knowledge with the DPHARM community, we help everyone improve the state of our industry for patients around the world. Together, we can be the innovative disruptors we're striving to be and make a difference in improving global health.'.

首席执行官Sam Srivastava补充说：“我们共同加速临床研究的使命超越了我们的WCG客户。”当我们能够与DPHARM社区分享我们的知识时，我们帮助每个人为世界各地的患者改善我们的行业状况。总之，我们可以成为我们努力成为的创新破坏者，并在改善全球健康方面发挥作用。

For more information, visit the WCG team at booth #53 at DPHARM, September 20 - 22, in Boston, MA.

欲了解更多信息，请访问马萨诸塞州波士顿9月20日至22日DPHARM 53号展位的WCG团队。

About WCG

关于WCG

WCG is a global leader of solutions that measurably improve and accelerate clinical research. Biopharmaceutical and medical device companies, contract research organizations (CROs), research institutions, and sites partner with us for our unmatched expertise, data intelligence, and purpose-built technology to make informed decisions and optimize study outcomes, while maintaining the highest standards of human participant protection.

WCG是可显着改善和加速临床研究的解决方案的全球领导者。生物制药和医疗器械公司，合同研究组织（CRO），研究机构和网站与我们合作，以获得无与伦比的专业知识，数据智能和专用技术，做出明智的决策并优化研究结果，同时保持最高标准人类参与者保护。

WCG raises the bar by pioneering new concepts, reimagining processes, fostering compliance and safety, and empowering those who perform clinical trials to accelerate the delivery of medical therapies and devices that improve lives. For more information, please visit wcgclinical.com or follow us on LinkedIn or Twitter @WCGClinical..

WCG通过开创新概念，重新设计流程，促进合规性和安全性以及授权进行临床试验的人员加速提供改善生活的医疗疗法和设备来提高标准。欲了解更多信息，请访问wcgclinical.com或在LinkedIn或Twitter@wcgclinical上关注我们。。

SOURCE WCG

源WCG